The choice of plasma-derived clotting factor concentrates

Research output: Contribution to journalArticle

Abstract

The gloomy picture caused by the AIDS epidemic is now particularly lightened by spectacular improvements in therapy. One important step forward toward elimination of the risk of transfusion of blood-borne infections by plasma products was the development of virucidal methods and their application to clotting factor concentrates. Another important advance was the production of ultrapure factor VIII concentrates by immuno-affinity chromatographic techniques. Not only are these concentrates at least as safe as less-pure concentrates in terms of transmission of blood-borne viral infections, but there is also a hint that the deteriorating immune system of HIV-positive haemophiliacs may be stabilized by these highly purified concentrates. Factor VIII produced by recombinant DNA technology is licensed for treatment of haemophilia A. Hopefully, it will be free of the risk of transmitting infections and will be available in sufficiently large amounts to meet the needs of haemophiliacs worldwide. The availability of concentrates containing only factor IX is another substantial step forward in the treatment of haemophilia B, while we wait for the cure of this disease through gene-transfer therapy.

Original languageEnglish
Pages (from-to)273-290
Number of pages18
JournalBailliere's Clinical Haematology
Volume9
Issue number2
DOIs
Publication statusPublished - 1996

Fingerprint

Blood Coagulation Factors
Factor VIII
Hemophilia B
Personal Autonomy
Factor IX
Recombinant DNA
Hemophilia A
Virus Diseases
Infection
Blood Transfusion
Genetic Therapy
Immune System
Acquired Immunodeficiency Syndrome
Therapeutics
HIV
Technology

ASJC Scopus subject areas

  • Hematology

Cite this

The choice of plasma-derived clotting factor concentrates. / Mannucci, P. M.

In: Bailliere's Clinical Haematology, Vol. 9, No. 2, 1996, p. 273-290.

Research output: Contribution to journalArticle

@article{fc56ccbdd0cb45beb33be58efaf9a621,
title = "The choice of plasma-derived clotting factor concentrates",
abstract = "The gloomy picture caused by the AIDS epidemic is now particularly lightened by spectacular improvements in therapy. One important step forward toward elimination of the risk of transfusion of blood-borne infections by plasma products was the development of virucidal methods and their application to clotting factor concentrates. Another important advance was the production of ultrapure factor VIII concentrates by immuno-affinity chromatographic techniques. Not only are these concentrates at least as safe as less-pure concentrates in terms of transmission of blood-borne viral infections, but there is also a hint that the deteriorating immune system of HIV-positive haemophiliacs may be stabilized by these highly purified concentrates. Factor VIII produced by recombinant DNA technology is licensed for treatment of haemophilia A. Hopefully, it will be free of the risk of transmitting infections and will be available in sufficiently large amounts to meet the needs of haemophiliacs worldwide. The availability of concentrates containing only factor IX is another substantial step forward in the treatment of haemophilia B, while we wait for the cure of this disease through gene-transfer therapy.",
author = "Mannucci, {P. M.}",
year = "1996",
doi = "10.1016/S0950-3536(96)80063-1",
language = "English",
volume = "9",
pages = "273--290",
journal = "Bailliere's Clinical Haematology",
issn = "0950-3536",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - The choice of plasma-derived clotting factor concentrates

AU - Mannucci, P. M.

PY - 1996

Y1 - 1996

N2 - The gloomy picture caused by the AIDS epidemic is now particularly lightened by spectacular improvements in therapy. One important step forward toward elimination of the risk of transfusion of blood-borne infections by plasma products was the development of virucidal methods and their application to clotting factor concentrates. Another important advance was the production of ultrapure factor VIII concentrates by immuno-affinity chromatographic techniques. Not only are these concentrates at least as safe as less-pure concentrates in terms of transmission of blood-borne viral infections, but there is also a hint that the deteriorating immune system of HIV-positive haemophiliacs may be stabilized by these highly purified concentrates. Factor VIII produced by recombinant DNA technology is licensed for treatment of haemophilia A. Hopefully, it will be free of the risk of transmitting infections and will be available in sufficiently large amounts to meet the needs of haemophiliacs worldwide. The availability of concentrates containing only factor IX is another substantial step forward in the treatment of haemophilia B, while we wait for the cure of this disease through gene-transfer therapy.

AB - The gloomy picture caused by the AIDS epidemic is now particularly lightened by spectacular improvements in therapy. One important step forward toward elimination of the risk of transfusion of blood-borne infections by plasma products was the development of virucidal methods and their application to clotting factor concentrates. Another important advance was the production of ultrapure factor VIII concentrates by immuno-affinity chromatographic techniques. Not only are these concentrates at least as safe as less-pure concentrates in terms of transmission of blood-borne viral infections, but there is also a hint that the deteriorating immune system of HIV-positive haemophiliacs may be stabilized by these highly purified concentrates. Factor VIII produced by recombinant DNA technology is licensed for treatment of haemophilia A. Hopefully, it will be free of the risk of transmitting infections and will be available in sufficiently large amounts to meet the needs of haemophiliacs worldwide. The availability of concentrates containing only factor IX is another substantial step forward in the treatment of haemophilia B, while we wait for the cure of this disease through gene-transfer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030013848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030013848&partnerID=8YFLogxK

U2 - 10.1016/S0950-3536(96)80063-1

DO - 10.1016/S0950-3536(96)80063-1

M3 - Article

C2 - 8800505

AN - SCOPUS:0030013848

VL - 9

SP - 273

EP - 290

JO - Bailliere's Clinical Haematology

JF - Bailliere's Clinical Haematology

SN - 0950-3536

IS - 2

ER -